Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Award Ceiling

$200,000

Estimated Total Program Funding

$200,000

This opportunity from National Institutes of Health is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.

Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:

• Nonprofits and 501(c)(3) organizations
• Small businesses and startups (especially for SBIR/STTR programs)
• State, local, and tribal governments
• Colleges, universities, and research institutions
• Individuals (for select programs in education, arts, and research)

Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.